Phathom Pharmaceuticals’ (PHAT) “Buy” Rating Reiterated at Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research report released on Friday, Marketbeat Ratings reports. They currently have a $28.00 target price on the stock. Several other equities analysts also recently weighed in on PHAT. Guggenheim dropped their target price on Phathom Pharmaceuticals […]
Needham & Company LLC reissued their buy rating on shares of Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) in a research report released on Friday, Marketbeat Ratings reports. They currently have a $28.00 target price on the stock. Several other equities analysts also recently weighed in on PHAT. Guggenheim dropped their target price on Phathom Pharmaceuticals […]
